Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
To access the live conference call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international), and refer to conference ID 1240499. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one precision therapy approved by the U.S. Food and Drug Administration and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2019-financial-results-on-thursday-february-13-2020-300999791.html
Investor and Media Contact: Jim Baker, 617-844-8236, firstname.lastname@example.org; Investor Contact: Kristin Hodous, 617-714-6674, email@example.com